ZNF703

ZNF703 (NLZ1/Zeppo1), a member of the NET/NLZ zinc-finger family, is a context-dependent transcriptional regulator that patterns development and drives epithelial tumorigenesis by controlling target gene expression (PMID:21317240, PMID:19014486). Its core repressive activity requires histone deacetylase function and promotes histone deacetylation at target promoters, and it complexes with Groucho co-repressors to silence targets such as E-cadherin while attenuating Wnt and TGFβ reporter activity in mammary epithelial cells (PMID:21317240, PMID:19014486). Structure-function analysis maps repression to the conserved Buttonhead domain rather than the Groucho-interaction domain, and identifies domains needed for proper nuclear localization (PMID:22886885, PMID:31164691). In tumor cells ZNF703 also acts as a sequence-specific activator: it directly binds the PEA15 enhancer to induce its expression, with nuclear translocation facilitated by interaction with HE4 (PMID:33246486). During development, ZNF703 functions downstream of Pax3/Zic1 and Foxj1a/Wnt signaling to control hindbrain patterning, neural crest formation, and motile ciliogenesis (PMID:26327644, PMID:29086464). Its protein abundance is restrained by the E3 ligase PARK2, which polyubiquitinates ZNF703 and targets it for proteasomal degradation, lowering Cyclin D1/E1 and enforcing G1 arrest (PMID:39043895).

1. 2008 High

   Established that NLZ1/ZNF703 is a transcriptional repressor and defined the biochemical requirement for its silencing activity, answering how it represses targets.

   Evidence Luciferase reporters across cell lines, pharmacological HDAC inhibition, transgenic zebrafish ChIP for histone acetylation, and domain-deletion analysis

   PMID:19014486

   Open questions at the time

   • Direct genomic targets in vivo not identified
   • Which HDAC complex is recruited not resolved
2. 2011 High

   Linked ZNF703 to breast cancer by showing it complexes with Groucho to repress E-cadherin and dampen Wnt/TGFβ reporters, framing it as a metastasis-promoting repressor.

   Evidence Reporter assays, co-IP with Groucho, knockdown/overexpression in cell lines and a mouse breast cancer metastasis model

   PMID:21317240

   Open questions at the time

   • Direct vs indirect binding at the E-cadherin promoter not distinguished
   • Whether Groucho is required for all targets unclear
3. 2011 Medium

   Defined the nuclear protein environment of ZNF703 by isolating a complex with DCAF7, PHB2, and NCOR2 and connected its overexpression to luminal/stem programs and progenitor expansion.

   Evidence Mass spectrometry/co-IP of the nuclear complex plus expression profiling and colony-forming assays in luminal breast cancer and normal breast epithelial cells

   PMID:21328542 PMID:21337521

   Open questions at the time

   • Functional roles of individual complex members not dissected
   • Direct target genes downstream of ER/E2F1 not validated by binding
4. 2011 Medium

   Connected ZNF703 to the actin/adhesion machinery by showing it promotes the metastasis-associated p120-catenin isoform 1 and alters p120 localization on ECM contact.

   Evidence Overexpression/knockdown in mammary epithelial cells with immunofluorescence and Western blotting

   PMID:21317240

   Open questions at the time

   • Mechanism of isoform switching not defined
   • Direct transcriptional control of p120 splicing not shown
5. 2013 Medium

   Extended ZNF703 signaling output to Akt/mTOR activation and ERα downregulation, providing a route to endocrine-therapy resistance.

   Evidence Overexpression/siRNA in breast cancer lines, Western blotting of pathway components, viability assays with mTOR inhibitor + tamoxifen

   PMID:23991038

   Open questions at the time

   • Whether Akt/mTOR activation is a direct transcriptional consequence unknown
   • Single lab, in vitro
6. 2013 Medium

   Resolved the domain architecture, assigning subcellular distribution and repression to specific conserved domains and showing the Groucho-interaction domain is dispensable for Groucho binding.

   Evidence Domain-deletion mutants with localization imaging, reporter assays, and co-IP

   PMID:22886885

   Open questions at the time

   • No structural model of the domains
   • Residue-level determinants of nuclear targeting not mapped
7. 2017 Medium

   Placed Znf703 in a developmental regulatory hierarchy, acting downstream of Pax3/Zic1 to repress posterior hindbrain genes and control neural crest formation.

   Evidence Morpholino knockdown and overexpression in Xenopus, microarray target identification, in situ hybridization

   PMID:29086464

   Open questions at the time

   • Direct hindbrain target promoters not identified
   • Mammalian relevance not tested
8. 2015 Medium

   Demonstrated a Wnt-integrated role in motile ciliogenesis, positioning Nlz1 downstream of Foxj1a/canonical Wnt and as a positive regulator of non-canonical Wnt11 signaling.

   Evidence Zebrafish morpholino knockdown with epistasis analysis against Foxj1a and Wnt pathway components

   PMID:26327644

   Open questions at the time

   • Transcriptional targets driving cilia formation unknown
   • Morpholino-based knockdown without genetic mutant confirmation
9. 2019 Medium

   Pinpointed the Buttonhead domain (not the Groucho-repression domain) as the determinant of repression required for mesoderm, neural crest, and placode development.

   Evidence Xenopus overexpression/knockdown with domain mutant analysis and in situ hybridization

   PMID:31164691

   Open questions at the time

   • Biochemical partner engaged by the Buttonhead domain unknown
   • Mechanism of RAR/Wnt induction of Znf703 not defined
10. 2020 High

    Identified direct DNA-binding activator function and a nuclear-import regulator: ZNF703 binds the PEA15 enhancer to activate transcription, with HE4 promoting its nuclear translocation.

    Evidence ChIP-seq, ChIP-PCR, dual-luciferase reporter, co-IP, immunofluorescence co-localization, and xenograft model in ovarian cancer

    PMID:33246486

    Open questions at the time

    • Determinants distinguishing activated vs repressed targets unclear
    • Whether HE4 regulates ZNF703 in other tissues unknown
11. 2020 Medium

    Broadened the activator repertoire to long non-coding RNA loci, showing promoter binding and transcriptional activation of LINC00460 and linc-UBC1.

    Evidence ChIP/RIP assays, JASPAR prediction, dual-luciferase reporters, and rescue experiments in ovarian cancer and glioma cells

    PMID:32271436 PMID:32382355

    Open questions at the time

    • linc-UBC1 binding rests on a single low-resolution assay (RIP + luciferase)
    • Direct vs indirect promoter occupancy not fully separated
12. 2024 High

    Defined post-translational control of ZNF703 abundance, showing PARK2 ubiquitinates and degrades it to restrain G1/S progression via Cyclin D1/E1.

    Evidence Co-IP, in vitro ubiquitination assay, proteasome inhibition, overexpression/knockdown, and xenograft model in high-grade serous ovarian cancer

    PMID:39043895

    Open questions at the time

    • Ubiquitinated lysine residues not mapped
    • Upstream signals regulating PARK2-ZNF703 axis unknown

• How ZNF703 switches between Groucho/HDAC-dependent repression and sequence-specific activation, and what selects its genomic targets, remains unresolved.
• No unifying DNA-binding motif or rule for activation vs repression
• No structural data on DNA engagement
• Mammalian developmental targets largely undefined